CLSD vs. IMUX, MDWD, CARM, COYA, TELO, CRVS, GLYC, IFRX, CDTX, and LPTX
Should you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Immunic (IMUX), MediWound (MDWD), Carisma Therapeutics (CARM), Coya Therapeutics (COYA), Telomir Pharmaceuticals (TELO), Corvus Pharmaceuticals (CRVS), GlycoMimetics (GLYC), InflaRx (IFRX), Cidara Therapeutics (CDTX), and Leap Therapeutics (LPTX). These companies are all part of the "medical" sector.
Clearside Biomedical (NASDAQ:CLSD) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
Clearside Biomedical currently has a consensus target price of $4.75, indicating a potential upside of 210.46%. Immunic has a consensus target price of $7.00, indicating a potential upside of 430.30%. Given Immunic's higher possible upside, analysts plainly believe Immunic is more favorable than Clearside Biomedical.
Clearside Biomedical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.
Immunic has a net margin of 0.00% compared to Clearside Biomedical's net margin of -394.91%. Immunic's return on equity of -157.44% beat Clearside Biomedical's return on equity.
Clearside Biomedical has higher revenue and earnings than Immunic. Clearside Biomedical is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 9.8% of Clearside Biomedical shares are owned by company insiders. Comparatively, 2.7% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Clearside Biomedical received 260 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 67.11% of users gave Clearside Biomedical an outperform vote while only 66.91% of users gave Immunic an outperform vote.
In the previous week, Clearside Biomedical had 1 more articles in the media than Immunic. MarketBeat recorded 3 mentions for Clearside Biomedical and 2 mentions for Immunic. Clearside Biomedical's average media sentiment score of 1.03 beat Immunic's score of 0.29 indicating that Clearside Biomedical is being referred to more favorably in the media.
Summary
Clearside Biomedical beats Immunic on 11 of the 16 factors compared between the two stocks.
Get Clearside Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Clearside Biomedical Competitors List
Related Companies and Tools